CSF3 and Miyoshi myopathy: The basic process is collecting CD34+ progenitor cells from peripheral blood of patients and mobilizing them by the granulocyte-colony stimulating factor (G-CSF) in earlier stages of MM treatment, then reserving them for the preparation of BCMA-targeted CAR-T cells.